Rethinking Tramadol: Large-Scale Review Challenges Its Status as a ‘Safer’ Opioid

A comprehensive new analysis of global clinical data is sounding an alarm for millions of patients relying on tramadol for chronic pain management. Long marketed as a “milder” and safer alternative to more potent opioids like oxycodone, tramadol may actually pose a significantly higher risk of serious heart complications while offering minimal pain relief, according to research published in BMJ Evidence-Based Medicine.

The study, led by a team from the Copenhagen University Hospital in Denmark, suggests that the potential harms of the drug—particularly cardiovascular events—likely outweigh its modest benefits for conditions like osteoarthritis, back pain, and fibromyalgia.

The Findings: A Double-Edged Sword

Researchers analyzed data from 19 randomized clinical trials involving 6,506 participants with various chronic pain conditions. The results were stark: patients taking tramadol were twice as likely to experience “serious adverse events” compared to those receiving a placebo.

The primary driver behind this increased risk was a surge in cardiac events. Specifically, the study linked tramadol use to higher rates of:

• Coronary artery disease (damage or disease in the heart’s major blood vessels)

• Chest pain (angina)

• Congestive heart failure

Equally concerning was the drug’s performance in its primary job: pain relief. While tramadol did reduce pain scores, the improvement was deemed “not clinically meaningful.” On a standard 10-point pain scale, tramadol reduced pain by less than one point on average, falling below the threshold that medical professionals consider a significant change for a patient’s quality of life.

Challenging the ‘Safe’ Narrative

For decades, tramadol (often sold under the brand name Ultram) has been the go-to prescription for clinicians wary of the “opioid crisis.” Because it is classified as a Schedule IV controlled substance in the U.S.—meaning it is perceived to have a lower potential for abuse than Schedule II drugs like morphine—its use has surged globally. In the United States alone, more than 16 million prescriptions were written in 2023.

“Often, we may use tramadol to avoid more addictive drugs like other opioids… though in fact tramadol is a synthetic opioid,” Dr. Marc Siegel, senior medical analyst, noted in a discussion regarding the study.

However, tramadol is chemically unique. Unlike traditional opioids, it also acts as a serotonin and norepinephrine reuptake inhibitor (SNRI). This “dual action” is what experts believe may be responsible for the heart-related side effects. Recent studies, including research published in EP Europace (2023), suggest tramadol may block specific cardiac sodium channels, potentially leading to arrhythmias or sudden cardiac death in susceptible individuals.

Expert Perspective: “Minimal Benefit, Significant Baggage”

Medical professionals not involved in the Danish study are urging caution but are not entirely surprised by the results.

“These findings echo what we see in clinical practice—medications like tramadol offer limited benefit for chronic pain while carrying significant risks,” said Dr. Adele Stewart, Chair of the RACGP Specific Interests Pain Management group. She emphasizes that chronic pain is often more about a sensitized nervous system than ongoing tissue damage, meaning pills that target only “nociception” (pain signals) often fail to provide lasting relief.

Dr. Mark Garofoli, a clinical assistant professor at West Virginia University and a pharmaceutical expert, noted that tramadol’s “baggage” is often underestimated. “We clinicians should amplify our respect for tramadol’s potential mixed-action side effects,” Garofoli stated, pointing out that for many patients—especially the elderly or those with kidney impairment—the risks are becoming increasingly difficult to justify.

Public Health Implications

The study comes at a critical time. Global opioid-related deaths remain at record highs, with nearly 600,000 fatalities in 2019 alone. The researchers argue that because tramadol carries a comparable risk of transitioning from acute to long-term use as other opioids, its widespread use should be “minimized to the greatest extent possible.”

Beyond the heart risks, the analysis confirmed a high frequency of “milder” but debilitating side effects:

• Nausea (1 in 7 patients)

• Dizziness (1 in 8 patients)

• Constipation (1 in 9 patients)

• Extreme sleepiness (1 in 13 patients)

A Balanced View: Limitations of the Study

While the findings are significant, some experts urge against panic. The Danish researchers acknowledged that many of the trials they reviewed had a “high risk of bias” and were relatively short-term, lasting only 2 to 16 weeks.

Dr. Marc Siegel cautioned that the link to heart disease in these trials might not account for all underlying health characteristics of the patients involved. “You would have to first look at underlying characteristics of that group who took the meds,” he noted, suggesting that further long-term, controlled studies are needed to prove direct causation.

What This Means for Patients

If you are currently taking tramadol for chronic pain, experts have one primary piece of advice: Do not stop taking the medication abruptly. Stopping opioids suddenly can trigger severe withdrawal symptoms. Instead, patients should schedule a consultation with their healthcare provider to discuss:

1. Alternative Therapies: Non-opioid options such as NSAIDs (if safe for the patient), physical therapy, or acupuncture.

2. Risk Assessment: Evaluating existing heart health or kidney function to see if tramadol remains a viable option.

3. Tapering Plans: If a change is needed, a doctor can help safely lower the dose over time.

“I recommend that clinicians and patients engage in transparent, shared decision-making that considers tramadol’s modest benefits alongside its risks,” said Dr. Alopi M. Patel, a pain medicine physician at the Icahn School of Medicine at Mt. Sinai.

As the medical community continues to re-evaluate the role of opioids in chronic care, the message from this latest research is clear: the “safer” alternative may not be as safe as once believed.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

https://www.livemint.com/science/health/this-popular-painkiller-tramadol-may-be-causing-you-more-harm-new-study-reveals-side-effects-heart-linked-risks-11766737842276.html